Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM3 | P20309 | 1/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
| ▸ | AR | P10275 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11997996 | 1.00 | CHRM3 (0.35) | CHRM3L3MBTL1KMT2AHTTAR | |
| SCHEMBL58010 | 1.00 | CHRM3 (0.35) | CHRM3L3MBTL1KMT2AHTTAR | |
| SCHEMBL13452774 | 0.93 | KMT2A (0.39) | CHRM3KMT2AHTT | |
| SCHEMBL12572936 | 0.93 | KMT2A (0.39) | CHRM3KMT2AHTT | |
| SCHEMBL20093387 | 0.93 | KMT2A (0.39) | CHRM3KMT2AHTT | |
| SCHEMBL23371066 | 0.91 | KMT2A (0.41) | CHRM3KMT2AHTT | |
| SCHEMBL21398646 | 0.91 | KMT2A (0.41) | CHRM3KMT2AHTT | |
| SCHEMBL15786185 | 0.91 | KMT2A (0.41) | CHRM3KMT2AHTT | |
| SCHEMBL17835201 | 0.86 | — | — | |
| SCHEMBL18269015 | 0.86 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 105 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240239813-A1 | KRAS INHIBITORS AND PHARMACEUTICAL USES THEREOF | Risen (Suzhou) Pharma Tech Co., Ltd. (CN) | 2024-07-18 | — | — | US | disclosed |
| US-11912723-B2 | KRAS modulators and uses thereof | QUANTA THERAPEUTICS, INC. (US) | 2024-02-27 | — | — | US | disclosed |
| US-20240018118-A1 | TRICYCLIC COMPOUNDS TO DEGRADE NEOSUBSTRATES FOR MEDICAL THERAPY | C 4 Therapeutics, Inc. (US) | 2024-01-18 | — | — | US | disclosed |
| US-11873291-B2 | Quinoline cGAS antagonist compounds | IMMUNESENSOR THERAPEUTICS, INC. (US) | 2024-01-16 | — | — | US | disclosed |
| US-20230381321-A1 | CAMPTOTHECIN CONJUGATES | SEAGEN INC. | 2023-11-30 | — | — | US | disclosed |
| US-20230374042-A1 | KRAS MODULATORS AND USES THEREOF | QUANTA THERAPEUTICS, INC. | 2023-11-23 | — | — | US | disclosed |
| US-20230357158-A1 | QUINOLINE cGAS ANTAGONIST COMPOUNDS | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM | 2023-11-09 | — | — | US | disclosed |
| US-11767330-B2 | Citrate salt, pharmaceutical compositions, and methods of making and using the same | FOGHORN THERAPEUTICS INC. (US) | 2023-09-26 | — | — | US | disclosed |
| US-20230142883-A1 | COMPOUNDS AND USES THEREOF | FOGHORN THERAPEUTICS INC. | 2023-05-11 | — | — | US | disclosed |
| US-20230133132-A1 | NAMPT MODULATORS | CYTOKINETICS, INC. | 2023-05-04 | — | — | US | disclosed |
| US-20120101114-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | PHARMACYCLICS, INC. (US) | 2012-04-26 | — | — | US | disclosed |
| US-20120065201-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | PHARMACYCLICS, INC. (US) | 2012-03-15 | — | — | US | disclosed |
| US-20110306587-A1 | UNSATURATED NITROGEN HETEROCYCLIC COMPOUNDS USEFUL AS PDE10 INHIBITORS | AMGEN INC. | 2011-12-15 | — | — | US | disclosed |
| US-20110245272-A1 | PYRIDO[4,3-B]INDOLES AND METHODS OF USE | MEDIVATION TECHNOLOGIES, INC. | 2011-10-06 | — | — | US | disclosed |
| US-20110224235-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE FOR THE TREATMENT OF SOLID TUMORS | PHARMACYCLICS, INC. (US) | 2011-09-15 | — | — | US | disclosed |
| EP-1235595-B1 | INTEGRIN-MEDIATED DRUG TARGETING | ALBERS MARKUS (DE) | 2009-08-05 | — | — | EP | disclosed |
| US-20080108576-A1 | Novel cytostatic conjugates with integrin ligands | BAYER AKTIENGESELLSCHAFT (DE) | 2008-05-08 | — | — | US | disclosed |
| US-7304037-B2 | Cytostatic conjugates with integrin ligands | BAYER AKIENGESELLSCHAFT (DE) | 2007-12-04 | — | — | US | disclosed |
| US-7220824-B1 | Integrin-mediated drug targeting | BAYER AKTIENGESELLSCHAFT (DE) | 2007-05-22 | — | — | US | disclosed |
| US-20040229911-A1 | New pharmaceutical combinations for NOS inhibitors | PFIZER INC | 2004-11-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (17 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110245272-A1 | PYRIDO[4,3-B]INDOLES AND METHODS OF USE | HTR3B, HTR4, HTR2C | CHRM3 79/4885L3MBTL1 4369/4885KMT2A 1364/4885 |
| US-11873291-B2 | Quinoline cGAS antagonist compounds | CGAS, GLS2, GLS | CHRM3 179/4885L3MBTL1 4285/4885KMT2A 4371/4885 |
| US-20230133132-A1 | NAMPT MODULATORS | NAMPT, MC4R, SIRT1 | CHRM3 2269/4885L3MBTL1 4152/4885KMT2A 1669/4885 |
| US-20080108576-A1 | Novel cytostatic conjugates with integrin ligands | ITGB3, ITGAV, ITGB5 | CHRM3 877/4885L3MBTL1 1718/4885KMT2A 4000/4885 |
| US-20230381321-A1 | CAMPTOTHECIN CONJUGATES | DCLRE1A, TOP2A, PAICS | CHRM3 4461/4885L3MBTL1 1130/4885KMT2A 2682/4885 |
| US-20230142883-A1 | COMPOUNDS AND USES THEREOF | VHL, TFEB, BECN1 | CHRM3 4850/4885L3MBTL1 815/4885KMT2A 682/4885 |
| US-11767330-B2 | Citrate salt, pharmaceutical compositions, and methods of making and using the same | CS, SMARCC2, SMARCC1 | CHRM3 4486/4885L3MBTL1 4679/4885KMT2A 1750/4885 |
| US-20230357158-A1 | QUINOLINE cGAS ANTAGONIST COMPOUNDS | CGAS, GLS2, GLS | CHRM3 179/4885L3MBTL1 4285/4885KMT2A 4371/4885 |
| US-20120101114-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | ABL1, BTK, ABL2 | CHRM3 4851/4885L3MBTL1 492/4885KMT2A 890/4885 |
| US-20040229911-A1 | New pharmaceutical combinations for NOS inhibitors | NOS1, NOS3, NPBWR1 | CHRM3 1214/4885L3MBTL1 2431/4885KMT2A 888/4885 |
| US-20230374042-A1 | KRAS MODULATORS AND USES THEREOF | KRAS, NRAS, HRAS | CHRM3 4032/4885L3MBTL1 3099/4885KMT2A 2868/4885 |
| US-20240018118-A1 | TRICYCLIC COMPOUNDS TO DEGRADE NEOSUBSTRATES FOR MEDICAL THERAPY | NFATC1, CTSS, MMP12 | CHRM3 4053/4885L3MBTL1 3664/4885KMT2A 1574/4885 |
| US-20110224235-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE FOR THE TREATMENT OF SOLID TUMORS | BTK, ABL1, LYN | CHRM3 4879/4885L3MBTL1 345/4885KMT2A 501/4885 |
| US-20240239813-A1 | KRAS INHIBITORS AND PHARMACEUTICAL USES THEREOF | KRAS, NRAS, HRAS | CHRM3 4869/4885L3MBTL1 3219/4885KMT2A 2630/4885 |
| US-20120065201-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | ABL1, BTK, ABL2 | CHRM3 4851/4885L3MBTL1 492/4885KMT2A 890/4885 |
| US-20110306587-A1 | UNSATURATED NITROGEN HETEROCYCLIC COMPOUNDS USEFUL AS PDE10 INHIBITORS | PDE10A, PDE2A, PDE3A | CHRM3 3613/4885L3MBTL1 4426/4885KMT2A 2900/4885 |
| US-11912723-B2 | KRAS modulators and uses thereof | KRAS, NRAS, HRAS | CHRM3 4032/4885L3MBTL1 3099/4885KMT2A 2868/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.